LCCC 1025: Phase II study of everolimus, trastuzumab, and vinorelbine for HER2+ breast cancer brain metastases (BCBM).
Carey K. Anders(Duke University), Lisa A. Carey(University of North Carolina at Chapel Hill), Lisle M. Nabell(Memorial Sloan Kettering Cancer Center), Hyman B. Muss(University of North Carolina at Chapel Hill), Elizabeth Claire Dees(University of North Carolina at Chapel Hill), Heejoon Jo(University of North Carolina at Chapel Hill), Julie Gottlieb Fisher(Carolinas Medical Center), Paul Little(University of North Carolina at Chapel Hill), Amanda Elyse Day Van Swearingen(University of North Carolina at Chapel Hill), Allison M. Deal(Memorial Sloan Kettering Cancer Center), D. Neil Hayes(University of North Carolina at Chapel Hill), Patrick M. Dillon(University of Virginia), Vandana G. Abramson(Vanderbilt University), J. Keith Smith(Merck & Co., Inc., Rahway, NJ, USA (United States)), Nikita Shah(Orlando Health), Timothy M. Zagar(University of North Carolina at Chapel Hill), Marni B. Siegel(University of North Carolina at Chapel Hill), Trevor A. Jolly(University of North Carolina at Chapel Hill), Shannon Puhalla(UPMC Hillman Cancer Center), Rita Nanda(University of Chicago)
Cited by 4
Related Papers
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
|JAMA|2017|2.3k
The molecular portraits of breast tumors are conserved across microarray platforms
|BMC Genomics|2006|1.5k
The chromatin accessibility landscape of primary human cancers
|Science|2018|1.4k